United Therapeutics Corporation Stock News

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its fourth quarter and full year 2021 financial r

Credit Suisse argues that BioMarin Pharmaceutical <>, United Therapeutics <>, and Insmed Incorporated <> still carry further upside opportunities in 2022, despite…

United Therapeutics (UTHR) said the world''s first recipient of a genetically-modified xenotransplanted organ, developed by the company, UHeart, reached a two-week milestone.Earlier

MannKind <> is trading higher after announcing that the FDA accepted the marketing application submitted by United Therapeutics <> for Tyvaso DPI.MannKind (MNKD) shares

In a last-ditch effort to save his life, doctors at the University of Maryland Medical Center have transplanted a genetically modified pig heart into patient David Bennett, a

These seven pharmaceutical stocks could create lucrative opportunities in the new year The post 7 Pharmaceutical Stocks That Could Make You Rich appeared first on InvestorPlace. More From InvestorPlac

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics' senior leaders will participate in a conversation hosted by J.P. Morgan biotech analyst Jessica Fye on January

United Therapeutics Corp (UTHR) shares closed today at 1.8% below its 52 week high of $217.75, giving the company a market cap of $9B. The stock is currently up 40.9% year-to-date, up 42.5% over the past 12 months, and up 49.5% over the past five years. This week, the Dow Jones Industrial Average rose 3.9%, and the S&P 500 rose 4.9%. Trading Activity Trading volume this week was 32.1% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.8. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , beats it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 6.5% The company's stock price performance over the past 12 months beats the peer average by 9.4% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is 22.6% higher than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

United Therapeutics Corp (UTHR) shares closed today at 1.3% below its 52 week high of $216.90, giving the company a market cap of $9B. The stock is currently up 41.0% year-to-date, up 42.9% over the past 12 months, and up 50.7% over the past five years. This week, the Dow Jones Industrial Average rose 1.6%, and the S&P 500 rose 2.3%. Trading Activity Trading volume this week was 13.7% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.8. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , beats it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 11.8% The company's stock price performance over the past 12 months beats the peer average by 15.6% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is 24.0% higher than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

United Therapeutics Corp (UTHR) shares closed today at 1.3% below its 52 week high of $216.90, giving the company a market cap of $9B. The stock is currently up 41.0% year-to-date, up 42.9% over the past 12 months, and up 50.7% over the past five years. This week, the Dow Jones Industrial Average rose 1.6%, and the S&P 500 rose 2.3%. Trading Activity Trading volume this week was 11.7% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.8. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , beats it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 11.8% The company's stock price performance over the past 12 months beats the peer average by 15.6% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is 24.0% higher than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

United Therapeutics Corp (UTHR) shares closed today at 1.3% below its 52 week high of $216.90, giving the company a market cap of $9B. The stock is currently up 41.0% year-to-date, up 43.3% over the past 12 months, and up 50.7% over the past five years. This week, the Dow Jones Industrial Average fell 0.5%, and the S&P 500 fell 0.3%. Trading Activity Trading volume this week was 11.7% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.8. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , beats it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 11.4% The company's stock price performance over the past 12 months beats the peer average by 14.6% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is 24.0% higher than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Related Stocks: UTHR ,

United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 3,082 shares of the businesss stock in a transaction that occurred on Monday, December 20th. The stock was sold at an average price of $200.00, for a total value of $616,400.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is []

Related Stocks: UTHR ,

Analysts predict that United Therapeutics Co. (NASDAQ:UTHR) will report earnings of $3.79 per share for the current fiscal quarter, Zacks reports. Five analysts have made estimates for United Therapeutics earnings, with estimates ranging from $3.60 to $3.91. United Therapeutics posted earnings per share of $2.19 during the same quarter last year, which indicates a positive []